Week 10 lands and the question stops being "is the protocol working" and becomes "which protocol is working for this nervous system." The DUTCH retest, the morning cortisol pull, the IGF-1, the subjective sleep score — together they sort you into one of three branches. Each branch has a different next protocol. The mistake is treating "didn't fully respond" as "do another ten weeks of the same thing." It almost never is.
What the data is actually telling you
The Phase 1 stack (DSIP nightly + Selank afternoon) and the Phase 2 layer (Epitalon ten-day pulse + Ipamorelin 100–200mcg pre-bed) work on three converging axes: HPA tone, GABAergic load, and pituitary pulse architecture. The Week 10 retest measures each axis independently. The salivary cortisol curve tells you HPA tone — is the morning peak present, is the evening trough actually a trough, is the slope reconstituting? The 6-sulfatoxymelatonin (if you ran it) tells you whether Epitalon recovered pineal output. IGF-1 tells you whether the Ipamorelin pulse is reaching the liver. Subjective sleep architecture — minutes to onset, wake events, refreshment score — tells you whether the GABAergic + delta-wave layer is holding.
Practitioner consensus on adrenal recovery uses a useful frame: people on identical protocols can present identical symptoms with opposite lab signatures, and that's what determines the next step. Two researchers both reporting "still tired at 3pm." One has a flattened cortisol curve and IGF-1 that climbed 38%. The other has a near-normal cortisol slope and IGF-1 that barely moved. Same complaint. Different problem. Different branch.
The other layer the substrate is explicit about: cortisol clearance matters as much as cortisol production. The DUTCH retest shows free cortisol AND metabolized cortisol — if free is low but metabolized is normal-to-high, you're clearing it too fast, not making too little. This changes the protocol entirely. Standard saliva panels miss this; the urine metabolite panel is what catches it.
Three branches, three protocols
Branch A — Clear responder
Signature: Cortisol curve reconstituted (morning peak >12 nmol/L salivary, evening trough <3, slope >0.5), IGF-1 up 30%+ from baseline, sleep onset <20min, ≤1 wake event per night, subjective refreshment 7+/10.
You're done with the intervention phase. Move directly to maintenance (Chapter 10). The mistake here is running another full cycle "to be safe" — the substrate is unambiguous: continuous administration of Epitalon provides no additional benefit while introducing unnecessary exposure. Ten days on, 110+ days off. DSIP can run nightly indefinitely. Selank stays on its 30/10 cycle. Ipamorelin drops to a pulsed schedule (Mon/Wed/Fri pre-bed, 100mcg) rather than nightly.
Branch B — Partial responder
Signature: Cortisol curve improved but still blunted (morning peak 8–12, slope 0.2–0.5), IGF-1 up 10–25%, sleep onset 20–40min, 2 wake events, refreshment 5–6/10.
This is the most common outcome and the branch where most people misdiagnose themselves. The protocol worked — partially. The substrate's pattern here points to one of three sub-causes, and the DUTCH metabolite panel tells you which:
B1 — Cortisol clearance is too fast (metabolized cortisol high, free cortisol low). The HPA is producing; the body is clearing it before tissues see it. Add licorice root extract (compounded with cortisol-supporting protocols in the substrate) at 500mg morning, 250mg early afternoon, for 6–8 weeks. This slows 11-beta-HSD2 conversion. Re-test at Week 16.
B2 — Pituitary pulse is weak (IGF-1 movement <20%, sleep architecture improved). The Ipamorelin dose is sub-threshold for your receptor density. Increase to 200–300mcg pre-bed, add a second pulse 4 hours into sleep if you're waking at 3am (CJC-1295 no-DAC 100mcg with the Ipamorelin pre-bed pulse extends the window). Run 6 more weeks.
B3 — Mitochondrial floor is the limiter (cortisol curve normalized, IGF-1 up, sleep markers improved, but daytime fatigue persists). The HPA is reset; the cells can't make ATP fast enough to feel it. This is the branch where the mitochondrial sub-protocol runs: Methylene Blue 0.5–1mg daily oral for 2–4 weeks to stabilize the electron transport chain, then layer MOTS-c 5–10mg SubQ 2–3x/week (fasted) for 12 weeks. The substrate is explicit on sequencing: Methylene Blue before MOTS-c, not concurrent — MB reduces baseline ROS so the AMPK activation from MOTS-c doesn't trigger paradoxical fatigue.
Branch C — Non-responder
Signature: Cortisol curve unchanged or worse, IGF-1 movement <10%, sleep markers unchanged, refreshment ≤4/10. Compliance verified (you actually ran the protocol, didn't skip, used clean reconstitution).
The protocol didn't fail — the lever was wrong. Non-response at Week 10 with verified compliance means the upstream driver is something the Sleep/Cortisol Path doesn't address. The substrate points hard at three:
- Subclinical autoimmune thyroid — TPO/TGA antibodies. Hashimoto's presents as cortisol dysregulation and sleep destruction long before TSH moves. Pull antibodies. If positive, the Hashimoto Path is foundational, not parallel.
- HPA-axis pathology upstream of cortisol — ACTH itself. The substrate names this as the first thing to measure when cortisol fails to respond to standard interventions. ACTH tells you whether the pituitary is signaling and the adrenals aren't listening, or whether the pituitary itself is the failure point. Different protocols.
- Mast cell / histamine load — chronic mast cell activation produces a cortisol presentation that mimics HPA dysfunction but is downstream of immune dysregulation. KPV (200–500mcg SubQ daily) for 4 weeks is the substrate's named intervention; if symptoms resolve, the lever was immune, not adrenal.
Protocol prescription — Branch B3 (Mitochondrial Rescue)
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| Methylene Blue | 0.5–1mg/kg | Oral, pharmaceutical grade only | Daily, 5 days on / 2 off | Expert | Run 2–4 weeks BEFORE introducing MOTS-c. Absolute contraindication with SSRIs/SNRIs/MAOIs (serotonin syndrome). |
| MOTS-c | 5–10mg | SubQ, abdomen | 2–3x/week, fasted (morning) | Expert | Start at 5mg, titrate to 10mg only after confirming no paradoxical fatigue. Cycle 12 weeks on, 4 weeks off — AMPK desensitization risk. |
| DSIP | 100–300mcg | SubQ | Nightly, continues | Expert | Continues from Phase 1. Do not discontinue during rescue protocol. |
| Ipamorelin | 100–200mcg | SubQ | Pre-bed, continues | Expert | Continues from Phase 2. |
| Magnesium glycinate | 400mg | Oral | Evening | Clinical | Substrate names magnesium as required for the 300+ enzymatic reactions including ATP synthesis MOTS-c amplifies. |
What's NOT happening yet
- The Branch A signature is not the goal for everyone. Branch B with the correct sub-protocol pivot lands at a better Week 20 than Branch A people who got lucky on the first stack — the diagnostic precision matters more than the speed.
- You are not running both the mitochondrial rescue AND a Phase 3 cortisol layer simultaneously. Pick the branch. The substrate is consistent: one upstream lever at a time, retest, then layer if needed.
- A "worse" cortisol slope at Week 10 is not protocol failure on its own. If subjective sleep improved and IGF-1 climbed, the HPA may be in active remodeling and the curve reconstitution is lagging — re-pull at Week 14 before pivoting.
- Antibodies, ACTH, and the mast cell workup are not Sleep/Cortisol Path content. If Branch C is your signature, the next step is a different Path, not a deeper version of this one.
Research describes these three branches. The lab data picks the one you're on. Track it. Adjust.